Insurers May Not Cover 2025–26 COVID Vaccine for Many Americans as Recommendations Narrow
FDA limited approval to people 65 and older and those under 65 with high‑risk conditions, leaving coverage and cost uncertain until CDC advisers weigh in Sept. 18–19
Federal changes to COVID‑19 vaccine recommendations this year could leave many Americans facing bills or unable to get a shot, health experts said, as insurers await guidance from the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP).
The Food and Drug Administration narrowed eligibility for the 2025–26 COVID vaccine to people aged 65 and older and younger people with underlying conditions that increase the risk of severe disease. Last year, shots were broadly recommended and covered for everyone 6 months and older. Insurers generally follow ACIP recommendations, and private coverage for vaccines recommended by ACIP is required under the Affordable Care Act. The ACIP is scheduled to review the FDA’s COVID vaccine recommendation on Sept. 18–19; its decision will shape which groups receive guaranteed insurance coverage.
Health systems and patients are already reporting mixed experiences. Centers for Disease Control and Prevention data from the 2024–25 season show one adult dose can cost as much as $141.80 when not covered by insurance, and providers may add an administration fee. Medicare, which must cover vaccines recommended by ACIP, has experienced technical problems that have led to erroneous charges for some beneficiaries, adding to confusion. "Given the tech issues, I’m not sure anyone can be worry‑free right now, but Medicare, people over 65, should not have an issue," said Dorit Reiss, a vaccine‑law expert and professor of law at the University of California, San Francisco.
Experts said people who clearly fall into the newly specified groups — older adults and those with well‑defined high‑risk conditions — are likely to have their shots covered once ACIP issues guidance. "People who have clear high risk shouldn't have an issue. People over 65 shouldn't have an issue. Everybody else may have an issue," Reiss said.
For people outside those categories, coverage is uncertain and varies by insurer and state. Insurers can take different approaches: they could treat last year’s broad recommendation as still in force until ACIP rules otherwise and continue coverage, or they could conclude that no universal recommendation exists and decline coverage. Some plans may elect to cover the shot voluntarily.
State actions have already altered access in pockets of the country. Massachusetts requires insurers to pay for COVID shots. Colorado mandates coverage by state‑regulated plans, and New York and Pennsylvania issued orders to ensure people can get vaccines without eligibility restrictions. Those measures may cover gaps left by federal guidance, but protections differ by state.
Pregnant people and children face particular uncertainty. The CDC’s public materials list pregnancy as a high‑risk condition, but federal messaging has been inconsistent. Reiss noted that the FDA had previously identified pregnancy as a high‑risk condition, yet the federal stance shifted. Professional groups such as the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists have continued to recommend vaccination for children and pregnant people, putting them at odds with the FDA’s narrower language and creating potential friction over coverage decisions.
"The way of doing this this year is just creating more chaos and confusion than ever before," said Cynthia Leifer, a professor of immunology at Cornell University College of Veterinary Medicine and contributing writer at Those Nerdy Girls. She warned that confusion among state regulators, insurers, pharmacies and clinicians is making it harder for people to get clear answers about eligibility and cost.
There are practical consequences for people seeking vaccines now. Some individuals have indicated on social media that they plan to misrepresent health histories to obtain the shot; experts warned that falsifying medical claims could lead to surprise bills. "If you want the insurance company to cover your vaccine, it’s probably not a good idea to try and go that route and lie to get the vaccine," Leifer said. She urged people to follow guidance from clinicians and insurers rather than misstate medical histories.
William Schaffner, a professor of preventive medicine at Vanderbilt University Medical Center, characterized the situation as an "extraordinary environment" and advised patience. He recommended that consumers call their insurers to confirm coverage but noted that calls made before the ACIP meeting may produce unclear answers. Waiting a few days after the committee issues guidance could give insurers time to update policies.
Public‑health experts emphasized the consequences of limited access. COVID vaccines reduce the likelihood of hospitalization, death and long COVID, and lower levels of community viral circulation. Ongoing uncertainty and administrative hurdles could depress uptake and increase risk for vulnerable populations.
People seeking clarity are advised to contact their health insurer and local health department, check state rules that might guarantee coverage, and ask providers whether a vaccine will be billed to insurance or require out‑of‑pocket payment. For Medicare beneficiaries, providers should be prepared to correct erroneous charges related to known technical issues.
Until ACIP issues a formal recommendation, the landscape for 2025–26 COVID vaccine coverage will remain uneven. The committee’s Sept. 18–19 meeting is likely to produce the clearest federal signal on who is entitled to insurance‑covered vaccines and how insurers will respond, but state policies and insurer decisions will continue to shape access for many Americans.